MENU
+Compare
CNADF
Stock ticker: OTC
AS OF
Apr 10 closing price
Price
$0.06
Change
-$0.00 (-0.00%)
Capitalization
3.09M

CNADF stock forecast, quote, news & analysis

CanadaBis Capital Inc is a vertically integrated cannabis company... Show more

CNADF
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for CNADF with price predictions
Feb 03, 2026

CNADF's Indicator enters downward trend

The Aroon Indicator for CNADF entered a downward trend on January 07, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 74 similar instances where the Aroon Indicator formed such a pattern. In of the 74 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis
Bullish Trend Analysis

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.501) is normal, around the industry mean (29.792). P/E Ratio (11.571) is within average values for comparable stocks, (74.095). CNADF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.035). CNADF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.029). P/S Ratio (0.251) is also within normal values, averaging (116.680).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CNADF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNADF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.75B. The market cap for tickers in the group ranges from 2.12K to 64.79B. MKKGY holds the highest valuation in this group at 64.79B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -2%. For the same Industry, the average monthly price growth was -2%, and the average quarterly price growth was 13%. CABR experienced the highest price growth at 27%, while SXTC experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 18%. For the same stocks of the Industry, the average monthly volume growth was -24% and the average quarterly volume growth was -67%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 63
Price Growth Rating: 58
SMR Rating: 80
Profit Risk Rating: 89
Seasonality Score: -19 (-100 ... +100)
View a ticker or compare two or three
CNADF
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
N/A
Address
PO Box 850
Phone
+1 888 784-4621
Employees
N/A
Web
https://www.canadabis.com